Men with metastatic Castrate Resistant Prostate Cancer (mCRPC) report significantly poorer quality of life (QoL) than other groups of men with prostate cancer. They experience fatigue, pain, and decreased physical activity. We at SHORE-C are conducting a 2 year study to explore the impact of systemic treatments on the quality of life of 130 UK men with mCRPC and their families.
In parallel we are conducting this confidential online survey with UK nurses, clinicians and other health care professionals to explore their views about treatments, side effects and decision making in men with mCRPC.
The study will provide important information to share with patients, prostate charity groups and health care professionals.
We would appreciate you completing the survey. It should take no longer than 15 minutes.
Dr Valerie Jenkins & Professor Dame Lesley Fallowfield from SHORE-C
Professors Heather Payne and Malcolm Mason
Please click Next to continue.